{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:30:20Z","timestamp":1792794620679,"version":"4.5.0"},"reference-count":26,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Chronic pelvic pain (CPP) is the main sequela of pelvic inflammatory disease (PID), with no established treatment. ZY5301 tablets, an effective part preparation extracted from <jats:italic>Ajuga decumbens<\/jats:italic> Thunb. (jingucao), are being tested as a treatment for CPP caused by PID.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate whether ZY5301 tablets are effective and safe for CPP treatment in women with PID.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This placebo-controlled double-blind, dose-parallel, phase 2 randomized clinical trial was conducted in 9 hospitals in China. Female participants with CPP after PID were enrolled between October 16, 2020, and August 31, 2021. The data analysis was performed between December 2021 and March 2022.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>Participants were randomized 1:1:1 to receive ZY5301 300 mg\/d, ZY5301 600 mg\/d, or placebo orally 3 times a day for 12 weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Visual analog scale (VAS) scores were the main measure used to evaluate the efficacy of ZY5301 in reducing CPP. The evaluation end points for VAS score included changes in mean weekly VAS score from baseline, area under the VAS score-time curve, pain remission (VAS score of 0 and 1) rate, and median time to pain remission. Safety was evaluated by the occurrence of treatment-emergent and treatment-related adverse events.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 180 women were randomly assigned, and 177 were included in the efficacy analysis; thus, the full analysis set included 60 participants in the ZY5301 mg\/d group (mean [SD] age, 37.4 [8.1] years), 58 in the ZY5301 600 mg\/d group (mean [SD] age, 37.1 [7.9] years), and 59 in the placebo group (mean [SD] age, 38.9 [7.3] years). Participant characteristics at baseline were similar among the groups. After 12 weeks of treatment, the mean (SD) change in VAS score from the baseline was \u22122.1 (1.7) points, \u22123.5 (1.5) points, and \u22123.8 (1.7) points in the placebo, ZY5301 300 mg\/d, and ZY5301 600 mg\/d groups, respectively (<jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001). The pain remission rates at week 12 were 43.3% and 53.5% in the ZY5301 300 mg\/d and ZY5301 600 mg\/d groups, respectively, a significant difference compared with the placebo group (11.9%; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001). All the other end points showed similar improvements. The ZY5301 600 mg\/d group had better efficacy than the ZY5301 300 mg\/d group, but the difference was not significant. The safety analysis revealed no significant differences among groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>These findings show that ZY5301 tablet is efficacious for the relief of CPP with acceptable tolerability.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05460546\">NCT05460546<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.23229","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T17:23:04Z","timestamp":1721755384000},"page":"e2423229","source":"Crossref","is-referenced-by-count":6,"title":["ZY5301 Tablet vs Placebo for Treatment of Chronic Pelvic Pain After Pelvic Inflammatory Disease"],"prefix":"10.1001","volume":"7","author":[{"given":"Xiuxiang","family":"Teng","sequence":"first","affiliation":[{"name":"Department of Gynecology, Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gynecology, The Second Affiliated Hospital of Heilongjiang University of Chinese Medicine, Harbin, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Defeng","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Luoyang First People\u2019s Hospital, Luoyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Beijing Hospital of Traditional Chinese Medicine Affiliated to Capital Medical University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Luoyang Hospital of Traditional Chinese Medicine, Luoyang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Zhongnan Hospital of Wuhan University, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxia","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Suzhou Hospital of Traditional Chinese Medicine, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianwei","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaifang","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, Shanghai Tongji Hospital, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gynecology, Guangxing Hospital Affiliated to Zhejiang Chinese Medicine University, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyu","family":"Wu","sequence":"additional","affiliation":[{"name":"Beijing Konruns Pharmaceutical Co Ltd, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Leng","sequence":"additional","affiliation":[{"name":"Beijing Konruns Pharmaceutical Co Ltd, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,7,23]]},"reference":[{"issue":"5","key":"zoi240736r1","first-page":"859","article-title":"The challenge of pelvic inflammatory disease.","volume":"73","author":"Crossman","year":"2006","journal-title":"Am Fam Physician"},{"issue":"12","key":"zoi240736r2","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1093\/infdis\/jiab116","article-title":"A review of the challenges and complexities in the diagnosis, etiology, epidemiology, and pathogenesis of pelvic inflammatory disease.","volume":"224","author":"Hillier","year":"2021","journal-title":"J Infect Dis"},{"issue":"3","key":"zoi240736r3","doi-asserted-by":"publisher","DOI":"10.1016\/j.disamonth.2021.101287","article-title":"Pelvic inflammatory disease in the adolescent and young adult: an update.","volume":"68","author":"Greydanus","year":"2022","journal-title":"Dis Mon"},{"issue":"3","key":"zoi240736r4","doi-asserted-by":"publisher","first-page":"80","DOI":"10.15585\/mmwr.mm6603a3","article-title":"Prevalence of pelvic inflammatory disease in sexually experienced women of reproductive age\u2014United States, 2013\u20132014.","volume":"66","author":"Kreisel","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"3","key":"zoi240736r6","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.ijantimicag.2015.05.004","article-title":"A review of antibiotic therapy for pelvic inflammatory disease.","volume":"46","author":"Duarte","year":"2015","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"zoi240736r7","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1067\/mob.2002.121625","article-title":"Effectiveness of inpatient and outpatient treatment strategies for women with pelvic inflammatory disease: results from the Pelvic Inflammatory Disease Evaluation and Clinical Health (PEACH) Randomized Trial.","volume":"186","author":"Ness","year":"2002","journal-title":"Am J Obstet Gynecol"},{"issue":"5 pt 1","key":"zoi240736r8","first-page":"934","article-title":"Lower quality of life among women with chronic pelvic pain after pelvic inflammatory disease.","volume":"102","author":"Haggerty","year":"2003","journal-title":"Obstet Gynecol"},{"issue":"10","key":"zoi240736r9","article-title":"Chronic pelvic pain: a comprehensive review.","volume":"14","author":"Juganavar","year":"2022","journal-title":"Cureus"},{"issue":"3","key":"zoi240736r10","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1097\/AOG.0000000000003716","article-title":"Chronic pelvic pain: ACOG practice bulletin, number 218.","volume":"135","author":"Committee on Practice Bulletins\u2014Gynecology","year":"2020","journal-title":"Obstet Gynecol"},{"key":"zoi240736r11","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/2046-4053-3-79","article-title":"The effectiveness of nonsteroidal anti-inflammatory agents in the treatment of pelvic inflammatory disease: a systematic review.","volume":"3","author":"Dhasmana","year":"2014","journal-title":"Syst Rev"},{"issue":"7","key":"zoi240736r12","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011603","article-title":"Amitriptyline for neuropathic pain in adults.","volume":"2015","author":"Moore","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"zoi240736r13","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011605","article-title":"Nortriptyline for neuropathic pain in adults.","volume":"1","author":"Derry","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"10255","key":"zoi240736r14","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/S0140-6736(20)31693-7","article-title":"Gabapentin for chronic pelvic pain in women (GaPP2): a multicentre, randomised, double-blind, placebo-controlled trial.","volume":"396","author":"Horne","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"zoi240736r15","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007115.pub3","article-title":"Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia.","volume":"2014","author":"Lunn","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"zoi240736r16","article-title":"Venlafaxine for neuropathic pain in adults.","volume":"2015","author":"Gallagher","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"zoi240736r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.fitote.2020.104764","article-title":"Harpagide: occurrence in plants and biological activities - a review.","volume":"147","author":"Frezza","year":"2020","journal-title":"Fitoterapia"},{"issue":"2","key":"zoi240736r18","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.jep.2013.03.048","article-title":"Pharmacokinetics of 8-O-acetylharpagide and harpagide after oral administration of Ajuga decumbens Thunb extract in rats.","volume":"147","author":"Wen","year":"2013","journal-title":"J Ethnopharmacol"},{"issue":"20","key":"zoi240736r19","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"6","key":"zoi240736r22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.17860","article-title":"Effect of mifepristone vs placebo for treatment of adenomyosis with pain symptoms: a randomized clinical trial.","volume":"6","author":"Che","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"4","key":"zoi240736r23","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/00007435-197710000-00001","article-title":"Acute pelvic inflammatory disease: characteristics of patients with gonococcal and nongonococcal infection and evaluation of their response to treatment with aqueous procaine penicillin G and spectinomycin hydrochloride.","volume":"4","author":"McCormack","year":"1977","journal-title":"Sex Transm Dis"},{"issue":"12","key":"zoi240736r24","first-page":"2637","article-title":"Effect of Fuyanshu Capsules combined with antibiotics on inflammatory factors in patients with pelvic inflammatory disease.","volume":"44","author":"Feng","year":"2019","journal-title":"Zhongguo Zhong Yao Za Zhi"},{"issue":"4","key":"zoi240736r25","first-page":"885","article-title":"The SF-12 as a population health measure: an exploratory examination of potential for application.","volume":"35","author":"Burdine","year":"2000","journal-title":"Health Serv Res"},{"issue":"2","key":"zoi240736r26","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s11136-004-0704-3","article-title":"Is the standard SF-12 health survey valid and equivalent for a Chinese population?","volume":"14","author":"Lam","year":"2005","journal-title":"Qual Life Res"},{"key":"zoi240736r20","volume-title":"Chinese Obstetrics and Gynecology","year":"2018","edition":"9th ed"},{"key":"zoi240736r5","unstructured":"Sexually transmitted infections treatment guidelines, 2021. Centers for Disease Control and Prevention. Accessed May 14, 2024. https:\/\/www.cdc.gov\/std\/treatment-guidelines\/toc.htm"},{"key":"zoi240736r21","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. National Cancer Institute. November 27, 2017. Accessed May 14, 2024. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2821390\/teng_2024_oi_240736_1720729861.09208.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T17:23:13Z","timestamp":1721755393000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2821390"}},"subtitle":["A Phase 2 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2024,7,23]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.23229","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,23]]}}}